Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 9.35 3.89% 0.35
TCON closed up 3.89 percent on Friday, February 26, 2021, on 1.62 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical TCON trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Doji - Bullish? Reversal 0.00%
Earnings Movers Other 0.00%
Lower Bollinger Band Touch Weakness 0.00%
MACD Bearish Centerline Cross Bearish 3.89%
Stochastic Reached Oversold Weakness 3.89%
Earnings Movers Other 3.89%
Down 3 Days in a Row Weakness 3.89%
Down 4 Days in a Row Weakness 3.89%
Oversold Stochastic Weakness 3.89%
Older End-of-Day Signals for TCON ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


TRACON Pharmaceuticals, Inc. Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Drugs Breast Cancer Treatment Of Breast Cancer Clinical Trial Macular Degeneration Carcinoma Blastoma Related Macular Degeneration Glioblastoma Sarcoma Targeted Therapy Colorectal Cancer Lung Cancer Age Related Macular Degeneration Hepatocellular Carcinoma Renal Cell Carcinoma Fibrotic Disease Fibrotic Diseases Therapeutics For Cancer Soft Tissue Sarcoma Transgene Sa

Is TCON a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.2
52 Week Low 0.95
Average Volume 608,166
200-Day Moving Average 5.37
50-Day Moving Average 9.93
20-Day Moving Average 10.17
10-Day Moving Average 10.16
Average True Range 0.99
ADX 26.47
+DI 13.08
-DI 28.16
Chandelier Exit (Long, 3 ATRs ) 8.80
Chandelier Exit (Short, 3 ATRs ) 10.92
Upper Bollinger Band 11.54
Lower Bollinger Band 8.80
Percent B (%b) 0.2
BandWidth 26.94
MACD Line -0.11
MACD Signal Line 0.10
MACD Histogram -0.2014
Fundamentals Value
Market Cap 127.95 Million
Num Shares 13.7 Million
EPS -1.02
Price-to-Earnings (P/E) Ratio -9.20
Price-to-Sales 0.00
Price-to-Book 8.09
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.04
Resistance 3 (R3) 11.87 10.81 11.59
Resistance 2 (R2) 10.81 10.13 10.89 11.44
Resistance 1 (R1) 10.08 9.70 10.45 10.25 11.29
Pivot Point 9.02 9.02 9.20 9.10 9.02
Support 1 (S1) 8.29 8.34 8.66 8.45 7.41
Support 2 (S2) 7.23 7.91 7.31 7.26
Support 3 (S3) 6.50 7.23 7.11
Support 4 (S4) 6.66